Preliminary Injunction Against Boston Scientific's Guidezilla(TM) Catheter Vacated by Federal Circuit

Preliminary Injunction Against Boston Scientific's Guidezilla(TM) Catheter
Vacated by Federal Circuit

MINNEAPOLIS, April 15, 2014 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc.
(Nasdaq:VASC) announced that a three judge panel of the U.S. Court of Appeals
for the Federal Circuit today vacated the preliminary injunction that was
previously issued by the District Court for the District of Minnesota
effective January 13, 2014 against Boston Scientific's Guidezilla guide
extension catheter. In its one paragraph opinion vacating the injunction, the
Court noted that a preliminary injunction is a "drastic and extraordinary
remedy that is not to be routinely granted" and "at this stage of the case the
record is too incomplete . . . to warrant the grant of a preliminary
injunction."

The Court's ruling on the preliminary injunction does not affect the
underlying patent litigation, which is currently scheduled to be ready for
trial on or after March 2015 in the District Court for the District of
Minnesota.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses
on developing unique clinical solutions for coronary and peripheral vascular
procedures.The company's product line consists of more than 80 products in
three categories: catheter products, hemostat products and vein
products.Vascular Solutions delivers its products to interventional
cardiologists, interventional radiologists, electrophysiologists, and vein
specialists through its direct U.S. sales force and international independent
distributor network.

The information in this press release contains forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially
from those anticipated in these forward-looking statements. Important factors
that may cause such differences include those discussed in our Annual Report
on Form 10-K for the year ended December 31, 2013 and other recent filings
with the Securities and Exchange Commission. The risks and uncertainties
include, without limitation, risks associated with the need for adoption of
our new products, lack of sustained profitability, exposure to intellectual
property claims, significant variability in quarterly results, exposure to
possible product liability claims, the development of new products by others,
doing business in international markets, the availability of third party
reimbursement, and actions by the FDA. The District Court grant of preliminary
injunction may be stayed or overturned on appeal, and the granting of a
preliminary injunction is not a determination of the ultimate merits of the
litigation, which will be determined by the presentation of evidence at trial
or in future dispositive motions.

For further information, connect to www.vasc.com.

CONTACT: Vascular Solutions, Inc.
         Howard Root, CEO
         HRoot@vasc.com
         (763) 656-4200
 
Press spacebar to pause and continue. Press esc to stop.